Lundbeck Q3 2019 Financial Results

International Markets - strategic brands up 38% in 9M 2019 * Grew 8% (8% in. L.C.) to DKK 3,022 million in 9M 2019 I Strategic brands# grew by 38% to DKK 549 million and constituted 18% of sales in 9M 2019 3.200 2.800 I 2.400 Rexulti increases from DKK 11 million to DKK 28 million 2.000 International Markets revenue (9M - DKKm) +8% Other products 240 180 International Markets - strategic brands (DKKm) +44% 11 Cipralex/Lexapro down 3% to DKK 1,283 million Main markets are Brazil, China, Japan and South Korea constituting -50% of sales in the region 1.600 1.200 800 400 0 9M.18 120 60 60 REXULTI A Abilify Maintena Brintellix 0 9M.19 Q3.17 Q3.18 Q3.19 #) Abilify Maintena, Rexulti and Brintellix/Trintellix Lundbeck

View entire presentation